CureVac NV

( )
CVAC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. 0.82%44.250.9%$1537.37m
JNJJohnson & Johnson -0.60%163.770.7%$982.08m
ABBVAbbVie, Inc. -1.30%106.331.9%$978.80m
MRKMerck & Co., Inc. 0.36%71.940.7%$799.95m
LLYEli Lilly & Co. 0.77%231.861.1%$599.11m
BMYBristol-Myers Squibb Co. -1.27%60.531.0%$545.22m
AZNAstraZeneca Plc 5.29%58.501.0%$274.88m
NVSNovartis AG -0.82%82.800.2%$167.64m
SNYSanofi -1.01%47.890.2%$136.30m
GSKGlaxoSmithKline Plc -0.23%38.840.2%$122.59m
RPRXRoyalty Pharma Plc -4.34%36.830.1%$113.92m
NVONovo Nordisk A/S -1.71%99.680.1%$107.46m
VTRSViatris, Inc. -1.77%13.330.0%$107.28m
RGENRepligen Corp. -0.28%306.056.8%$102.70m
APLSApellis Pharmaceuticals, Inc. -3.36%33.060.0%$93.67m

Company Profile

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.